Christopher J. McDonald, a member of the Firm’s Antitrust Practice Group, represents businesses, associations and individuals injured by anticompetitive activities. Mr. McDonald’s practice also involves prosecuting complex securities fraud cases on behalf of institutional investors.

In the antitrust field, Mr. McDonald represented end-payors (e.g., union health and welfare funds and consumers) of the prescription drug TriCor® in the In re TriCor Indirect Purchaser Antitrust Litigation, where he obtained a $65.7 million settlement on behalf of plaintiffs and the class.

In the securities field, Mr. McDonald is currently prosecuting In re Schering-Plough Corporation/ENHANCE Securities Litigation to recover losses investors suffered after the disclosure of negative clinical trial data for Vytorin®, a fixed-dose combination pill comprised of ezitimibe (Schering-Plough’s Zetia®) and simvastatin (Merck & Co., Inc.’s Zocor®). He was also part of the team that litigated In re Bristol-Myers Squibb Securities Litigation, where Labaton Sucharow was able to secure a $185 million settlement and meaningful corporate governance reforms on behalf of Bristol-Myers Squibb shareholders following negative disclosures about omapatrilat, an experimental hypertension drug. The settlement with BMS is the largest ever obtained against a pharmaceutical company in a securities fraud case that did not involve a restatement of financial results.

A litigator for most of his career, Mr. McDonald also has in-house and regulatory experience. As a senior attorney with a telecommunications company he regularly addressed legal, economic and public policy issues before state public utility commissions.

During his time at Fordham University School of Law, Mr. McDonald was on the Law Review.

Mr. McDonald is a member of the New York State Bar Association and the Association of the Bar of the City of New York.